论文部分内容阅读
用国产基因工程乙肝疫苗 ５μｇ／支 ｘ ３按 ０、１、 ２程序对１３４名新生儿（母亲产前 ＨＢｓＡｇ（＋） ４７名，ＨＢｓＡｇ（－）８７名）免疫接种，免后观察１２个月。结果新生儿接种疫苗后均无局部及全身不良反应。免后 Ｔ７、 Ｔ１２抗－ＨＢｓ阳性率分别为 ８３．５８％及 ８７．４０％；抗－ ＨＢｓ滴度均值分别为 １５７．５６、 １２６．９２。免前检测抗－ＨＢｓ（－）的６７名新生儿，免后Ｔ７及Ｔ１２检测抗－ＨＢｓ阳转率分别为８０．６０％（５４／６７）、８３．５８％（５６／６７），免后Ｔ７检出ＨＢｓＡｇ阳性婴儿２名，阳性率４．２６％（占母亲ＨＢｓＡｇ（＋）），乙肝传播阻断率（保护率）９１．４８％。结果显示，乙肝基因疫苗具有良好的安全性和免疫原性，可取代血源性乙肝疫苗进行全面推广应用。
134 newborn babies (mothers prenatal HBsAg (+) 47, HBsAg (-) 87) were vaccinated with domestic genetic engineering hepatitis B vaccine 5μg / branch x 3 according to the 0,1,2 procedures. After 12 months . Results No neonatal local and systemic adverse reactions after vaccination. The positive rates of T7 and T12 anti-HBs were 83.58% and 87.40% respectively after immunization. The mean titers of anti-HBs were 157.56 and 126.92, respectively. Pretreatment anti-HBs (-) in 67 newborns, after free T7 and T12 detection of anti-HBs positive rates were 80.60% (54/67), 83.58% (56/67), respectively After T7 detected 2 HBsAg positive infants, the positive rate of 4.26% (accounting for the mother HBsAg (+)), hepatitis B transmission rate (protection rate) 91.48%. The results showed that the hepatitis B gene vaccine has good safety and immunogenicity, which can replace the blood-borne hepatitis B vaccine for comprehensive promotion and application.